Can Caffeine Reduce the Chances of Parkinson’s Disease? A Review
DOI:
https://doi.org/10.47611/jsrhs.v13i3.7052Keywords:
caffeine, parkinson's disease, PD, alzheimer's disease, dopamine, acetylcholine, adenosine, receptor, attenuation, neuroprotection, coffee, stimulant drug, neurodegeneration, prevent parkinson's, reduce parkinson's, benefits of caffeine, neurodegenerative disorders, neuroprotective benefitsAbstract
Finding therapies for preventing Parkinson’s Disease (PD), a major neurodegenerative disease, remains an important way to improve the quality of life and reduce the total number of those afflicted with PD worldwide. Caffeine, one of the world’s most consumed psychoactive drugs, affects neurological pathways that are involved in PD. In this review, we explore the relationship between caffeine and PD, its mechanisms, and how the onset of PD is affected by the consumption of caffeine. We propose that daily caffeine consumption may reduce the risk of developing PD later in life, but that the neuroprotective effect varies by several factors. Understanding the effects of caffeine and how it impacts PD may provide insight into potential treatments or delay the onset of disease
Downloads
References or Bibliography
“13C-Caffeine Breath Test Identifies Single Nucleotide Polymorphisms Associated with Caffeine Metabolism.” 2020. Drug Metabolism and Pharmacokinetics 35 (3): 321–28.
Altman, Robert D., and Anthony E. Lang. 2011. “Caffeine in Parkinson’s Disease: A Pilot Open-Label, Dose-Escalation Study.” Movement Disorders: Official Journal of the Movement Disorder Society 26 (13): 2427–31.
Arendash, G. W., W. Schleif, K. Rezai-Zadeh, E. K. Jackson, L. C. Zacharia, J. R. Cracchiolo, D. Shippy, and J. Tan. 2006. “Caffeine Protects Alzheimer’s Mice against Cognitive Impairment and Reduces Brain β-Amyloid Production.” Neuroscience 142 (4): 941–52.
Berridge, Kent C., and Morten L. Kringelbach. 2015. “Pleasure Systems in the Brain.” Neuron 86 (3): 646.
Bjorness, Theresa E., and Robert W. Greene. 2009. “Adenosine and Sleep.” Current Neuropharmacology 7 (3): 238.
Brown, Tracy. 2021. “Coffee Consumption.” British Coffee Association. October 26, 2021. https://britishcoffeeassociation.org/coffee-consumption/.
“Caffeine.” 2020. The Nutrition Source. July 30, 2020. https://www.hsph.harvard.edu/nutritionsource/caffeine/.
———. n.d. Accessed August 17, 2023. https://go.drugbank.com/drugs/DB00201#pharmacology.
“Caffeine Consumption.” 1996. Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association 34 (1): 119–29.
“Caffeine Intake Increases the Rate of Bone Loss in Elderly Women and Interacts with Vitamin D Receptor Genotypes.” 2001. The American Journal of Clinical Nutrition 74 (5): 694–700.
“Caffeine Overdose.” n.d. Accessed August 18, 2023. https://medlineplus.gov/ency/article/002579.htm.
Calabresi, P., A. Stefani, N. B. Mercuri, and G. Bernardi. 1989. “Acetylcholine-Dopamine Balance in Striatum: Is It Still a Target for Antiparkinsonian Therapy?” Central Cholinergic Synaptic Transmission, 315–21.
Chen, Yanchun, Yuan Zhang, Mengnan Zhang, Hongxi Yang, and Yaogang Wang. 2022. “Consumption of Coffee and Tea with All-Cause and Cause-Specific Mortality: A Prospective Cohort Study.” BMC Medicine 20. https://doi.org/10.1186/s12916-022-02636-2.
Cieślak, Marek, Michał Komoszyński, and Andrzej Wojtczak. 2008. “Adenosine A2A Receptors in Parkinson’s Disease Treatment.” Purinergic Signalling 4 (4): 305–12.
“Cognitive Functions of Cortical Acetylcholine: Toward a Unifying Hypothesis.” 1997. Brain Research Reviews 23 (1-2): 28–46.
Conger, S. A., G. L. Warren, and M. A. Hardy. 2011. “Does Caffeine Added to Carbohydrate Provide Additional Ergogenic Benefit for Endurance?” International Journal of Sport Nutrition and Exercise Metabolism 21 (1). https://doi.org/10.1123/ijsnem.21.1.71.
Cornelis, Marilyn C., Ahmed El-Sohemy, Edmond K. Kabagambe, and Hannia Campos. 2006. “Coffee, CYP1A2 Genotype, and Risk of Myocardial Infarction.” JAMA: The Journal of the American Medical Association 295 (10): 1135–41.
Costa, J., N. Lunet, C. Santos, J. Santos, and A. Vaz-Carneiro. 2010. “Caffeine Exposure and the Risk of Parkinson’s Disease: A Systematic Review and Meta-Analysis of Observational Studies.” Journal of Alzheimer’s Disease: JAD 20 Suppl 1. https://doi.org/10.3233/JAD-2010-091525.
“Crude Caffeine Reduces Memory Impairment and Amyloid β1–42 Levels in an Alzheimer’s Mouse Model.” 2012. Food Chemistry 135 (3): 2095–2102.
Daly, J. W., J. Holmén, and B. B. Fredholm. 1998. “[Is Caffeine Addictive? The Most Widely Used Psychoactive Substance in the World Affects Same Parts of the Brain as Cocaine].” Lakartidningen 95 (51-52). https://pubmed.ncbi.nlm.nih.gov/9889511/.
Department of Health, and Human Services. n.d. “Caffeine.” Accessed July 21, 2023. http://www.betterhealth.vic.gov.au/health/healthyliving/caffeine.
“Dopamine, a Neurotransmitter, Influences the Immune System.” 2000. Journal of Neuroimmunology 102 (2): 113–24.
“Dopamine: A Potential Substrate for Synaptic Plasticity and Memory Mechanisms.” 2003. Progress in Neurobiology 69 (6): 375–90.
“Dopamine in Parkinson’s Disease.” 2021. Clinica Chimica Acta; International Journal of Clinical Chemistry 522 (November): 114–26.
Duarte-Araújo, Margarida, Carlos Nascimento, M. Alexandrina Timóteo, Teresa Magalhães-Cardoso, and Paulo Correia-de-Sá. 2004. “Dual Effects of Adenosine on Acetylcholine Release from Myenteric Motoneurons Are Mediated by Junctional Facilitatory A2A and Extrajunctional Inhibitory A1 Receptors.” British Journal of Pharmacology 141 (6): 925.
“Emptying and Absorption of Caffeine from the Human Stomach.” 1971. Gastroenterology 61 (6): 838–43.
Eskelinen, M. H., and M. Kivipelto. 2010. “Caffeine as a Protective Factor in Dementia and Alzheimer’s Disease.” Journal of Alzheimer’s Disease: JAD 20 Suppl 1. https://doi.org/10.3233/JAD-2010-1404.
Evans, Justin, John R. Richards, and Amanda S. Battisti. 2023. “Caffeine.” In StatPearls [Internet]. StatPearls Publishing.
Ferré, Sergi. 2010. “Role of the Central Ascending Neurotransmitter Systems in the Psychostimulant Effects of Caffeine.” Journal of Alzheimer’s Disease: JAD 20 (Suppl 1): S35.
Ferré, Sergi, Kjell Fuxe, Bertil B. Fredholm, Micaela Morelli, and Patrizia Popoli. 1997. “Adenosine–dopamine Receptor–receptor Interactions as an Integrative Mechanism in the Basal Ganglia.” Trends in Neurosciences 20 (10): 482–87.
“Functional Changes of the Basal Ganglia Circuitry in Parkinson’s Disease.” 2000. Progress in Neurobiology 62 (1): 63–88.
Gandhi, Kavita R., and Abdolreza Saadabadi. 2023. “Levodopa (L-Dopa).” In StatPearls [Internet]. StatPearls Publishing.
“Genetics, Coffee Consumption, and Parkinson’s Disease.” 2022. September 23, 2022. https://www.cdc.gov/genomics/hugenet/casestudy/parkinson/parkcoffee_view.htm#:~:text=Parkinson’s%20disease%20(PD)%20is%20the,neurodegenerative%20disease%20after%20Alzheimer's%20disease.
Gepshtein, Sergei, Xiaoyan Li, Joseph Snider, Markus Plank, Dongpyo Lee, and Howard Poizner. 2014. “Dopamine Function and the Efficiency of Human Movement.” Journal of Cognitive Neuroscience 26 (3): 645.
Green, P. J., R. Kirby, and J. Suls. 1996. “The Effects of Caffeine on Blood Pressure and Heart Rate: A Review.” Annals of Behavioral Medicine: A Publication of the Society of Behavioral Medicine 18 (3). https://doi.org/10.1007/BF02883398.
Grider, Michael H., Rishita Jessu, and Rian Kabir. 2023. “Physiology, Action Potential.” In StatPearls [Internet]. StatPearls Publishing.
Han, Ji Won, Yebin D. Ahn, Won-Seok Kim, Cheol Min Shin, Seong Jin Jeong, Yoo Sung Song, Yun Jung Bae, and Jong-Min Kim. 2018. “Psychiatric Manifestation in Patients with Parkinson’s Disease.” Journal of Korean Medical Science 33 (47). https://doi.org/10.3346/jkms.2018.33.e300.
Harris, Haley N., and Yuan B. Peng. 2020. “Evidence and Explanation for the Involvement of the Nucleus Accumbens in Pain Processing.” Neural Regeneration Research 15 (4): 597.
Hjelmstad, Gregory O. 2004. “Dopamine Excites Nucleus Accumbens Neurons through the Differential Modulation of Glutamate and GABA Release.” The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 24 (39): 8621.
Hong, Chien Tai, Lung Chan, and Chyi-Huey Bai. 2020. “The Effect of Caffeine on the Risk and Progression of Parkinson’s Disease: A Meta-Analysis.” Nutrients 12 (6). https://doi.org/10.3390/nu12061860.
Institute of Medicine (US) Committee on Military Nutrition Research. 2001. “Pharmacology of Caffeine.” In Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Operations. National Academies Press (US).
Jankovic, J. 2008. “Parkinson’s Disease: Clinical Features and Diagnosis.” Journal of Neurology, Neurosurgery, and Psychiatry 79 (4): 368–76.
Jenner, P. 2014. “An Overview of Adenosine A2A Receptor Antagonists in Parkinson’s Disease.” International Review of Neurobiology 119. https://doi.org/10.1016/B978-0-12-801022-8.00003-9.
Katz, David L., Kim Doughty, and Ather Ali. 2011. “Cocoa and Chocolate in Human Health and Disease.” Antioxidants & Redox Signaling 15 (10): 2779.
Kim, Jee Wook, Min Soo Byun, Dahyun Yi, Jun Ho Lee, So Yeon Jeon, Gijung Jung, Han Na Lee, et al. 2019. “Coffee Intake and Decreased Amyloid Pathology in Human Brain.” Translational Psychiatry 9. https://doi.org/10.1038/s41398-019-0604-5.
Kim, Se Jung, Jee Young Sung, Ji Won Um, Nobutaka Hattori, Yoshikuni Mizuno, Keiji Tanaka, Seung R. Paik, Jongsun Kim, and Kwang Chul Chung. 2003. “Parkin Cleaves Intracellular α-Synuclein Inclusions via the Activation of Calpain *.” The Journal of Biological Chemistry 278 (43): 41890–99.
Kolahdouzan, Mahshad, and Mazen J. Hamadeh. 2017. “The Neuroprotective Effects of Caffeine in Neurodegenerative Diseases.” CNS Neuroscience & Therapeutics 23 (4): 272.
Lanciego, José L., Natasha Luquin, and José A. Obeso. 2012. “Functional Neuroanatomy of the Basal Ganglia.” Cold Spring Harbor Perspectives in Medicine 2 (12). https://doi.org/10.1101/cshperspect.a009621.
Lara, Beatriz, Carlos Ruiz-Moreno, Juan José Salinero, and Juan Del Coso. 2019. “Time Course of Tolerance to the Performance Benefits of Caffeine.” PloS One 14 (1): e0210275.
Lara, D. R. 2010. “Caffeine, Mental Health, and Psychiatric Disorders.” Journal of Alzheimer’s Disease: JAD 20 Suppl 1. https://doi.org/10.3233/JAD-2010-1378.
“Launch of WHO’s Parkinson Disease Technical Brief.” n.d. Accessed July 28, 2023. https://www.who.int/news/item/14-06-2022-launch-of-who-s-parkinson-disease-technical-brief.
Lazarus, Michael, Hai-Ying Shen, Yoan Cherasse, Wei-Min Qu, Zhi-Li Huang, Caroline E. Bass, Raphaelle Winsky-Sommerer, et al. 2011. “Arousal Effect of Caffeine Depends on Adenosine A2A Receptors in the Shell of the Nucleus Accumbens.” The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 31 (27): 10067.
Lean, Michael E. J., and Alan Crozier. 2012. “Coffee, Caffeine and Health: What’s in Your Cup?” Maturitas 72 (3): 171–72.
Liu, Rui, Xuguang Guo, Yikyung Park, Xuemei Huang, Rashmi Sinha, Neal D. Freedman, Albert R. Hollenbeck, Aaron Blair, and Honglei Chen. 2012. “Caffeine Intake, Smoking, and Risk of Parkinson Disease in Men and Women.” American Journal of Epidemiology 175 (11): 1200.
Liu, Ying‐jiao, Jiao Chen, Xun Li, Xin Zhou, Yao‐mei Hu, Shi‐feng Chu, Ye Peng, and Nai‐hong Chen. 2019. “Research Progress on Adenosine in Central Nervous System Diseases.” CNS Neuroscience & Therapeutics 25 (9): 899.
Maia, L., and A. De Mendonça. 2002. “Does Caffeine Intake Protect from Alzheimer’s Disease?” European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies 9 (4): 377–82.
Manalo, Rafael V. M., and Paul M. B. Medina. 2018. “Caffeine Protects Dopaminergic Neurons From Dopamine-Induced Neurodegeneration via Synergistic Adenosine-Dopamine D2-Like Receptor Interactions in Transgenic Caenorhabditis Elegans.” Frontiers in Neuroscience 12 (March): 315825.
Marsden, Charles A. 2006. “Dopamine: The Rewarding Years.” British Journal of Pharmacology 147 (S1): S136–44.
Maughan, R. J., and J. Griffin. 2003. “Caffeine Ingestion and Fluid Balance: A Review.” Journal of Human Nutrition and Dietetics: The Official Journal of the British Dietetic Association 16 (6). https://doi.org/10.1046/j.1365-277x.2003.00477.x.
McCall, A. L., W. R. Millington, and R. J. Wurtman. 1982. “Blood-Brain Barrier Transport of Caffeine: Dose-Related Restriction of Adenine Transport.” Life Sciences 31 (24). https://doi.org/10.1016/0024-3205(82)90715-9.
McLellan, Tom M., Doug G. Bell, and Gary H. Kamimori. 2004. “Caffeine Improves Physical Performance During 24 H of Active Wakefulness,” August. https://www.ingentaconnect.com/content/asma/asem/2004/00000075/00000008/art00003.
Murray, Alexandra, and Jeremy Traylor. 2023. “Caffeine Toxicity.” In StatPearls [Internet]. StatPearls Publishing.
National Institute on Drug Abuse. n.d. “Drugs and the Brain.” National Institute on Drug Abuse. Accessed February 4, 2024. https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/drugs-brain.
Nehlig, A. 2010. “Is Caffeine a Cognitive Enhancer?” Journal of Alzheimer’s Disease: JAD. https://www.ncbi.nlm.nih.gov/pubmed/20182035.
Ning, Y. L., N. Yang, X. Chen, Z. A. Zhao, X. Z. Zhang, X. Y. Chen, P. Li, Y. Zhao, and Y. G. Zhou. 2015. “Chronic Caffeine Exposure Attenuates Blast-Induced Memory Deficit in Mice.” Chinese Journal of Traumatology = Zhonghua Chuang Shang Za Zhi / Chinese Medical Association 18 (4). https://doi.org/10.1016/j.cjtee.2015.10.003.
Nirogi, Ramakrishna, Koteshwara Mudigonda, Vishwottam Kandikere, and Ranjithkumar Ponnamaneni. 2010. “Quantification of Acetylcholine, an Essential Neurotransmitter, in Brain Microdialysis Samples by Liquid Chromatography Mass Spectrometry.” Biomedical Chromatography: BMC 24 (1): 39–48.
Olguín, Hugo Juárez, David Calderón Guzmán, Ernestina Hernández García, and Gerardo Barragán Mejía. 2016. “The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress.” Oxidative Medicine and Cellular Longevity 2016. https://doi.org/10.1155/2016/9730467.
Paoletti, Federico Paolini, Nicola Tambasco, and Lucilla Parnetti. 2019. “Levodopa Treatment in Parkinson’s Disease: Earlier or Later?” Annals of Translational Medicine 7 (Suppl 6). https://doi.org/10.21037/atm.2019.07.36.
“Parkinson Disease.” n.d. Accessed August 29, 2023. https://www.who.int/news-room/fact-sheets/detail/parkinson-disease.
“Parkinson’s Disease.” 2015. The Lancet 386 (9996): 896–912.
“Parkinson’s Disease.” 2022. Harvard Health. March 31, 2022. https://www.health.harvard.edu/a_to_z/parkinsons-disease-a-to-z.
“Parkinson’s Disease.” 2023. Mayo Clinic. May 26, 2023. https://www.mayoclinic.org/diseases-conditions/parkinsons-disease/symptoms-causes/syc-20376055.
“Parkinson’s Disease.” n.d. National Institute of Neurological Disorders and Stroke. Accessed July 28, 2023. https://www.ninds.nih.gov/health-information/disorders/parkinsons-disease.
“Parkinson’s Disease - Causes.” n.d. Nhs.uk. Accessed August 29, 2023. https://www.nhs.uk/conditions/parkinsons-disease/causes/.
“Parkinson’s Disease: Causes, Symptoms, and Treatments.” n.d. National Institute on Aging. Accessed July 21, 2023. https://www.nia.nih.gov/health/parkinsons-disease.
Poewe, Werner. 2006. “The Natural History of Parkinson’s Disease.” Journal of Neurology 253 (7): vii2–6.
Popoli, P., C. Frank, M. T. Tebano, R. L. Potenza, A. Pintor, M. R. Domenici, V. Nazzicone, A. Pèzzola, and R. Reggio. 2003. “Modulation of Glutamate Release and Excitotoxicity by Adenosine A2A Receptors.” Neurology 61 (11 Suppl 6). https://doi.org/10.1212/01.wnl.0000095216.89483.a2.
Prediger, R. D. 2010. “Effects of Caffeine in Parkinson’s Disease: From Neuroprotection to the Management of Motor and Non-Motor Symptoms.” Journal of Alzheimer’s Disease: JAD 20 Suppl 1. https://doi.org/10.3233/JAD-2010-091459.
PubChem. n.d. “Caffeine.” Accessed August 18, 2023. https://pubchem.ncbi.nlm.nih.gov/compound/2519.
Qi, Hui, and Shixue Li. 2014. “Dose–response Meta-Analysis on Coffee, Tea and Caffeine Consumption with Risk of Parkinson’s Disease.” Geriatrics & Gerontology International 14 (2): 430–39.
Reichert, Carolin Franziska, Tom Deboer, and Hans‐peter Landolt. 2022. “Adenosine, Caffeine, and Sleep–wake Regulation: State of the Science and Perspectives.” Journal of Sleep Research 31 (4). https://doi.org/10.1111/jsr.13597.
Ren, Xiangpeng, and Jiang-Fan Chen. 2020. “Caffeine and Parkinson’s Disease: Multiple Benefits and Emerging Mechanisms.” Frontiers in Neuroscience 14 (December): 602697.
Ribeiro, Joaquim A., and Ana M. Sebastião. 2010. “Caffeine and Adenosine.” Journal of Alzheimer’s Disease: JAD 20 (s1): S3–15.
Rizzi, Giorgio, and Kelly R. Tan. 2017. “Dopamine and Acetylcholine, a Circuit Point of View in Parkinson’s Disease.” Frontiers in Neural Circuits 11 (December): 315586.
Ross, Ashley E., and B. Jill Venton. 2015. “Adenosine Transiently Modulates Stimulated Dopamine Release in the Caudate Putamen via A1 Receptors.” Journal of Neurochemistry 132 (1): 51.
Sam, Christian, and Bruno Bordoni. 2023. “Physiology, Acetylcholine.” In StatPearls [Internet]. StatPearls Publishing.
Santos, Catarina, João Costa, João Santos, António Vaz-Carneiro, and Nuno Lunet. 2010. “Caffeine Intake and Dementia: Systematic Review and Meta-Analysis.” Journal of Alzheimer’s Disease: JAD 20 (s1): S187–204.
Schreiner, Thomas Gabriel, and Bogdan Ovidiu Popescu. 2022. “Impact of Caffeine on Alzheimer’s Disease Pathogenesis—Protective or Risk Factor?” Life 12 (3). https://doi.org/10.3390/life12030330.
Sebastião, Ana M., and Joaquim A. Ribeiro. 2009. “Adenosine Receptors and the Central Nervous System.” Adenosine Receptors in Health and Disease, 471–534.
Sheffler, Zachary M., Vamsi Reddy, and Leela Sharath Pillarisetty. 2023. “Physiology, Neurotransmitters.” In StatPearls [Internet]. StatPearls Publishing.
Shen, Hai-Ying, and Jiang-Fan Chen. 2009. “Adenosine A2A Receptors in Psychopharmacology: Modulators of Behavior, Mood and Cognition.” Current Neuropharmacology 7 (3): 195.
Solinas, Marcello, Sergi Ferré, Zhi-Bing You, Marzena Karcz-Kubicha, Patrizia Popoli, and Steven R. Goldberg. 2002. “Caffeine Induces Dopamine and Glutamate Release in the Shell of the Nucleus Accumbens.” The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 22 (15): 6321.
Sonne, James, Vamsi Reddy, and Morris R. Beato. 2022. “Neuroanatomy, Substantia Nigra.” In StatPearls [Internet]. StatPearls Publishing.
Sun, Xiaojuan, Wei-Dong Chen, and Yan-Dong Wang. 2015. “β-Amyloid: The Key Peptide in the Pathogenesis of Alzheimer’s Disease.” Frontiers in Pharmacology 6 (September): 164010.
Sveinbjornsdottir, Sigurlaug. 2016. “The Clinical Symptoms of Parkinson’s Disease.” Journal of Neurochemistry 139 (July): 318–24.
“Targets for Neuroprotection in Parkinson’s Disease.” 2009. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1792 (7): 676–87.
Tarnopolsky, Mark A. 2011. “Caffeine and Creatine Use in Sport.” Annals of Nutrition & Metabolism 57 (Suppl. 2): 1–8.
Taylor, Sara B., Candace R. Lewis, and M. Foster Olive. 2013. “The Neurocircuitry of Illicit Psychostimulant Addiction: Acute and Chronic Effects in Humans.” Substance Abuse and Rehabilitation 4: 29.
Teleanu, Raluca Ioana, Adelina-Gabriela Niculescu, Eugenia Roza, Oana Vladâcenco, Alexandru Mihai Grumezescu, and Daniel Mihai Teleanu. 2022. “Neurotransmitters—Key Factors in Neurological and Neurodegenerative Disorders of the Central Nervous System.” International Journal of Molecular Sciences 23 (11). https://doi.org/10.3390/ijms23115954.
Temple, Jennifer L. 2009. “Caffeine Use in Children: What We Know, What We Have Left to Learn, and Why We Should Worry.” Neuroscience and Biobehavioral Reviews 33 (6): 793.
“Therapeutic Potential of Adenosine A2A Receptor Antagonists in Parkinson’s Disease.” 2005. Pharmacology & Therapeutics 105 (3): 267–310.
Thorn, Caroline F., Eleni Aklillu, Teri E. Klein, and Russ B. Altman. 2012. “PharmGKB Summary: Very Important Pharmacogene Information for CYP1A2.” Pharmacogenetics and Genomics 22 (1): 73.
Triarhou, Lazaros C. 2013. “Dopamine and Parkinson’s Disease.” In Madame Curie Bioscience Database [Internet]. Landes Bioscience.
Tsuboi, Yoshio. 2012. “Environmental-Genetic Interactions in the Pathogenesis of Parkinson’s Disease.” Experimental Neurobiology 21 (3): 123.
Vizi, S. E., A. Rónai, L. Hársing, and J. Knoll. 1977. “Inhibitory Effect of Dopamine on Acetylcholine Release from Caudate Nucleus.” Polish Journal of Pharmacology and Pharmacy 29 (3). https://pubmed.ncbi.nlm.nih.gov/887499/.
Walter, Kristin. 2022. “Caffeine and Health.” JAMA: The Journal of the American Medical Association 327 (7): 693–693.
Webster Ross, G., Robert D. Abbott, Helen Petrovitch, David M. Morens, Andrew Grandinetti, Ko-Hui Tung, Caroline M. Tanner, et al. 2000. “Association of Coffee and Caffeine Intake With the Risk of Parkinson Disease.” JAMA: The Journal of the American Medical Association 283 (20): 2674–79.
Winston, Anthony P., Elizabeth Hardwick, and Neema Jaberi. 2005. “Neuropsychiatric Effects of Caffeine.” Advances in Psychiatric Treatment 11 (6): 432–39.
Yager, Lindsay M., Aaron F. Garcia, Amanda M. Wunsch, and Susan M. Ferguson. 2015. “The Ins and Outs of the Striatum: Role in Drug Addiction.” Neuroscience 301 (August): 529.
Yamada-Fowler, Naomi, and Peter Söderkvist. 2015. “Coffee, Genetic Variants, and Parkinson’s Disease: Gene–Environment Interactions.” Journal of Caffeine Research 5 (1): 3.
Yang, Amy, Abraham A. Palmer, and Harriet de Wit. 2010. “Genetics of Caffeine Consumption and Responses to Caffeine.” Psychopharmacology 211 (3): 245.
Yang, Wenya, Jamie L. Hamilton, Catherine Kopil, James C. Beck, Caroline M. Tanner, Roger L. Albin, E. Ray Dorsey, et al. 2020. “Current and Projected Future Economic Burden of Parkinson’s Disease in the U.S.” NPJ Parkinson’s Disease 6. https://doi.org/10.1038/s41531-020-0117-1.
Zhai, Shenyu, Asami Tanimura, Steven M. Graves, Weixing Shen, and D. James Surmeier. 2018. “Striatal Synapses, Circuits, and Parkinson’s Disease.” Current Opinion in Neurobiology 48 (February): 9.
Zhang, Y. F., and S. J. Cragg. 2021. “Revisiting Dopamine-Acetylcholine Imbalance in Parkinson’s Disease: Glutamate Co-Transmission as an Exciting Partner in Crime.” Neuron 109 (7). https://doi.org/10.1016/j.neuron.2021.03.018.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Dagur Hjaltason
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
